Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 20/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.53 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22532205 | 0.88 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22532122 | 0.88 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL29444668 | 0.88 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL29444687 | 0.88 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL29748940 | 0.88 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22532141 | 0.88 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22012867 | 0.82 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31497525 | 0.82 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL24599408 | 0.79 | PIK3CG (0.41) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22532441 | 0.78 | PIK3CG (0.58) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20220213096-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO LTD (CN) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | PIK3CG 8/4885PIK3CD 3/4885PIK3R1 19/4885 |
| US-20220213096-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | PIK3CG 8/4885PIK3CD 3/4885PIK3R1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.